BioCentury
ARTICLE | Company News

AstraZeneca, Insmed deal

October 10, 2016 7:00 AM UTC

AstraZeneca granted Insmed exclusive, worldwide rights to INS1007 (formerly AZD7986), a small molecule targeting dipeptidyl peptidase-1 ( DPP-1; CTSC). AZ will receive $30 million up front and is ...